{"classes":[{"categories":[{"measurements":[{"comment":"Could not be estimated due to the low number of events at the time of analysis","groupId":"OG000","lowerLimit":"4.5","upperLimit":"NA","value":"6.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Duration of response was measured for participants in remission (CR/CRh\\*), and was measured from the time the participant first achieved remission until first documented relapse or death from disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of the last bone marrow assessment or the last survival follow-up visit to confirm remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their date of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieved a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.\n\nThe initial dose was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 and for all subsequent cycles of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"MEDIAN","populationDescription":"Participants who received an infusion of blinatumomab and with a CR or CRh\\* response during the first 2 treatment cycles.","reportingStatus":"POSTED","timeFrame":"Up to the data cut-off date of 20 May 2015; median observation time was 7.0 months","title":"Duration of CR or CRh* Response","type":"SECONDARY","unitOfMeasure":"months"}